Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion.

Ou, Lanzi; Tang, Yicong; Deng, Yanming; Guo, Lijie; He, Qingqing; He, Tingting; Feng, Weineng

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion.

Ou, Lanzi; Tang, Yicong; Deng, Yanming; Guo, Lijie; He, Qingqing; He, Tingting; Feng, Weineng.

Afiliación

Ou L; Oncology, Guangdong Medical University, Zhanjiang, China.
Tang Y; Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China.
Deng Y; Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China.
Guo L; Department of Head and Neck/Thoracic Medical Oncology, The First People's Hospital of Foshan, Foshan, China.
He Q; Medical Department Shanghai OrigiMed Co., Ltd, Shanghai, China.
He T; Medical Department Shanghai OrigiMed Co., Ltd, Shanghai, China.
Feng W; Medical Department Shanghai OrigiMed Co., Ltd, Shanghai, China.

Front Oncol ; 12: 911362, 2022.

Article en En | MEDLINE | ID: mdl-35957915

Palabras clave

CUX1-MET fusion; EGFR mutations; icotinib plus crizotinib; lung adenocarcinoma; partial response

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China